mTOR抑制剂在去势抵抗性前列腺癌中的研究进展
| 作者: |
1张金明,
1王璐,
1王宏磊,
1徐万海
1 哈尔滨医科大学附属第四医院泌尿外科，哈尔滨 150001 |
| 通讯: |
徐万海
Email: xuwanhai@hrbmu.edu.cn |
| DOI: | 10.3978/j.issn.2095-6959.2021.05.023 |
摘要
哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin，mTOR)是磷脂酰肌醇-3羟基激酶/蛋白激酶B/mTOR(PI3K/Akt/mTOR)信号通路中的关键蛋白，与肿瘤细胞的发生发展存在密切联系，参与肿瘤细胞的侵袭与转移。在去势抵抗性前列腺癌(castration resistant prostate cancer，CRPC)中，约有50%的病例的PI3K/Akt/mTOR信号通路过度激活，且PI3K/Akt/mTOR信号通路的异常活化通常是诱导前列腺癌向CRPC进展的原因。这表明靶向针对该途径的治疗方法可能在提高患者生存率方面具备显著疗效。本文以期通过总结CRPC中PI3K/Akt/mTOR通路的生物学特点、功能、治疗及联合用药，为CRPC寻找新的分子治疗靶点提供参考。
关键词：
去势抵抗性前列腺癌；mTOR通路；治疗靶点
Research progress of mTOR inhibitors in castration resistant prostate cancer
CorrespondingAuthor: XU Wanhai Email: xuwanhai@hrbmu.edu.cn
DOI: 10.3978/j.issn.2095-6959.2021.05.023
Abstract
The mammalian target of rapamycin is a key protein in the PI3K/Akt/mTOR signaling pathway, which is closely related to not only tumorigenesis but also tumor invasion and metastasis. Excessive activation of PI3K/Akt/mTOR signaling pathway occurs in nearly 50% of castration resistant prostate cancer (CRPC) cases, and the abnormal activation of the PI3K/Akt/mTOR signaling pathway is often responsible for the development from the prostate cancer to CRPC. This suggests that targeting treatments for this pathway may have significant efficacy in improving the patient survival rate. This article aims to provide a reference for CRPC to find a novel molecular therapeutic target by summarizing the biological characteristics, function, treatment and combination of PI3K/Akt/mTOR pathway in CRPC.
Keywords：
castration resistant prostate cancer; mTOR pathway; therapeutic target